---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-270961"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-23T00:37:56.838005+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ResMed Q1 FY23 revenue $950.3M (+5% YoY, +9% CC); GAAP EPS $1.43, non-GAAP $1.51

## Summary
- Revenue $950.3M, up 5% YoY (9% constant currency); Americas (ex-SaaS) revenue up 18%.
- GAAP operating profit $275.7M (+5%), non-GAAP operating profit $290.8M (+4%).
- GAAP diluted EPS $1.43 vs $1.39; non-GAAP diluted EPS $1.51 flat YoY.
- Board declared quarterly dividend $0.44/share, payable Dec 15, 2022, record Nov 10.
- Acquired mementor (German digital sleep medicine); opened new R&D facility in Ireland.

## SEC filing metadata
- accession: 0001193125-22-270961
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312522270961/0001193125-22-270961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312522270961/d416189d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-270961
- JSON: https://secwatch.observer/filing/0001193125-22-270961.json
- Plain text: https://secwatch.observer/filing/0001193125-22-270961.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.